Global Companion Diagnostics Partnering Deal Trends, Players, Financials and Forecasts Report 2010-2017

Dublin, Oct. 30, 2017 -- The "Global Companion Diagnostics Partnering 2010-2017: Deal trends, players, financials and forecasts" report has been added to Research and Markets' offering.

The Global Companion Diagnostics Partnering 2010-2017 report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Companion Diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

The report takes the reader through a comprehensive review Companion Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Companion Diagnostics partnering deals.

The report presents financial deal term values for Companion Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

One of the key highlights of the report is that over 350 online deal records of actual Companion Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

Key benefits

• In-depth understanding of Companion Diagnostics deal trends since 2010
• Access to headline, upfront, milestone and royalty data
• Analysis of the structure of Companion Diagnostics agreements with numerous real life case studies
• Detailed access to actual Companion Diagnostics contracts entered into by leading biopharma companies
• Identify most active Companion Diagnostics dealmakers since 2010
• Insight into terms included in a Companion Diagnostics partnering agreement, with real world examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Available deals are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific therapy target
• Technology type
  

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Companion Diagnostics dealmaking

Chapter 3 - Leading Companion Diagnostics deals

Chapter 4 - Most active Companion Diagnostics dealmakers

Chapter 5 - Companion Diagnostics contracts dealmaking directory

Chapter 6 - Companion Diagnostics dealmaking by technology type

Chapter 7 - Partnering resource center

For more information about this report visit https://www.researchandmarkets.com/research/2m26r7/global_companion

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Diagnostics, In Vitro Diagnostics